CX-614 is a positive allosteric modulator of AMPA receptors, shows neuroprotective effects for treatment of Parkinson's disease and Alzheimer's disease.

CX 4338 (CX4338, CX-4338) is a potent, selective CXCR2 inhibitor that selectively inhibits CXCR2-mediated recruitment of β-arrestin-2 with IC50 of 6.3 uM.

CWP-232228 is a highly potent small-molecule Wnt/β-catenin signaling inhibitor that targets the β-catenin/Tcf4 interaction in the nucleus.

CVT-12012 is a potent and orally bioavailable stearoyl-coA desaturase (SCD) inhibitor, with IC50s of 38 nM, 6.1 nM for rat microsomal and human HEPG2, respectively.

Cuspin-1 is a small molecule upregulator of SMN (Survival of Motor Neuron protein) with EC50 of 18 uM.

CUR-61414 is a small molecule Hedgehog (Hh) inhibitor that can block elevated Hh signaling activity resulting from oncogenic mutations in Patched-1, binds directly with Smoothened (Ki=44 nM).

CU-3 (DGKα inhibitor CU-3) is a is a novel potent, selective diacylglycerol kinase α (DGKα) inhibitor with IC50 of 0.6 uM, targets the catalytic region, but not the regulatory region.

CU239 is a novel non-retinoid RPE65 inhibitor that selectively inhibits isomerase activity of RPE65 with IC50 of 6 uM.

CTS-1027 is a potent small molecule inhibitor of MMPs(IC50=0.4 nM/0.6 nM for MMP2/MMP13); >1,000 fold selectivity over MMP1.

CTPB is an anacardic acid derivative, was reported as a selective activator of p300 (KAT3B) HAT activity but not PCAF (KAT2B), which enhanced HAT-dependent transcriptional activation.

CTN06 is a potent Etk (BMX) and Btk dual inhibitor with IC50 of 200 and 50 nM, respectively.

CTDP-32476 is a potent and selective dopamine transporter (DAT) inhibitor and a competitive inhibitor of cocaine binding to the DAT with Ki of 12 nM.

CTA095 (CTA-095) is a potent Etk (BMX) and Src dual inhibitor with IC50 of 60 and 120 nM, respectively, shows no significant inhibition on Btk and Yes at 10 uM.

CTA056 (CTA 056) is a potent, selective inhibitor of interleukin-2-inducible T-cell kinase (Itk) with IC50 of ~100 nM, also inhibits Btk (IC50=400 nM), but shows no significant inhibition for Etk (BMX kinase, IC50=5 uM).

CT-707 (Conteltinib) is a novel multikinase inhibitor targeting FAK (IC50=1.6 nM), ALK and Pyk2, exerts synergistic antitumor effects against hepatocellular carcinoma in vitro and in vivo.

CSRM617 hydrochloride (CSRM-617) is a small-molecule inhibitor of the transcription factor ONECUT2 (OC2) with Kd of 7.43 uM in SPR assays, binds to OC2-HOX domain directly.

CSN5i-3 (CSN5 inhibitor 3) is a potent, selective and orally available inhibitor of CSN5 with IC50 of 5.8 nM, the proteolytic subunit of COP9 signalosome (CSN).

CSLP43 (RIPK2 inhibitor CSLP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.

CSIC E379 is a potent, selective uncoupling proteins UCP1/UCP2 inhibitor with EC50 of 20 uM/30 uM, respectively.

CS-526 (AKU 517.

CS3 is a potent, selective cIAP1 and cIAP2 inhibitor with IC50 of 16 nM and 85 nM respectively, shows no significant activity against XIAP (IC50>34 uM)..

Crotamiton is a drug that is used both as a scabicidal (for treating scabies) and as a general antipruritic. It is a prescription lotion based medicine that is applied to the whole body to get rid of the scabies parasite.

Cromolyn sodium is an antiallergic drug.

Cromoglicic acid is a mast cell stabilizer with anti-inflammatory activity that prevents the release of inflammatory chemicals such as histamine, leukotrienes from mast cells.

Crisdesalazine (AAD-2004, AAD2004) is a derivative of aspirin that inhibits microsomal PGE(2) synthase-1 (mPGES-1) activity in response to both LPS-treated BV2 cell with IC50 of 230 nM and recombinant human mPGES-1 protein with IC50 of 249 nM in vitro.

cRIPGBM (RIPGBM derivative cRIPGBM, RIPGBM-18) is a metabolite of RIPGBM induces apoptosis in GBM CSCs (EC50=68 nM in GBM 1 cells) by interacting with RIPK2 (Kd=2.3 uM).

CR6086 (CR-6086) is a potent, selective prostaglandin E2 receptor 4 (EP4) antagonist with Ki of 16.6 nM (hEP4 receptor), inhibits PGE2-stimulated cAMP production with IC50 of 22 nM.

CPTH6 is a thiazole derivative that can reduce histone acetylation and histone acetyltransferase (HAT) activity in human leukemia cells, CPTH6 is a specific Gcn5/pCAF inhibitor.

CPTH6 hydrobromide is a thiazole derivative that can reduce histone acetylation and histone acetyltransferase (HAT) activity in human leukemia cells, CPTH6 is a specific Gcn5/pCAF inhibitor.

CPTH2 is a specific histone acetyltransferase inhibitor modulating Gcn5 network in vitro and in vivo, inhibits H3 acetylation and induces cell-cycle perturbation and apoptosis in U-937 cells.